

# Intra- and Extra-Hepatic Cholangiocarcinoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy:  1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+  Maint ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Biomarkers/Characteristics: (select all that apply)

Microsatellite Instability:  dMMR/MSI-H  MSI-L  Not Reported NTRK Fusion:  Negative  Positive  Not Reported

NTRK Fusion:  Negative  Positive  Not Reported  Unknown

## Unresectable and Metastatic Disease | First Line of Therapy (1st Line)

Gemcitabine and cisplatin

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**

